Dataset from A 52-week Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Empagliflozin Once Daily, as an add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009758
下载链接
链接失效反馈官方服务：
资源简介：
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group,
efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with
Type 2 Diabetes Mellitus with insufficient glycaemic control
创建时间：
2025-06-24
